ARID1A and neoplasm: Our findings demonstrate a clear genetic dosage effect of ARID1A loss in pancreatic cancer, as homozygous deletion (KARL/L) led to more aggressive tumour progression and shorter survival compared to heterozygous deletion (KARL/+).